Cost-effectiveness of obinutuzumab plus bendamustine in Chinese patients with relapse and refractory follicular lymphoma

A decision analytic model was constructed to assess the cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab maintenance therapy (O-B-O) in Chinese patients with relapsed and refractory follicular lymphoma (rrFL). O-B-O was associated with a dominant or more favorable cost-effectiveness than the conventional therapies. Survival outcomes, quality of life of progressionfree survival, and subsequent treatment costs for progressive disease were the main drivers of the costeffectiveness of O-B-O. The cost-effectiveness proportions of O-B-O relative to conventional therapies under the recommended cost-effectiveness threshold ranged from 61.0% to 99.9%. Thus, O-B-O was highly cost-effective for treating patients with rrFL in China compared with conventional therapies. Plain language summary: In this study, researchers used a decision-making model to figure out if a treatment called obinutuzumab plus bendamustine followed by obinutuzumab maintenance therapy (OB-O) is a good value for money for Chinese patients with a certain type of lymphoma (follicular lymphoma) that has come back or doesn't respond well to previous treatment (relapsed and refractory follicular lymphoma, rrFL). They found that O-B-O is a better choice in terms of cost-effectiveness compared with traditional treatments for Chinese patients with rrFL. Factors like how long patients live, their quality of life without the disease getting worse, and the costs of subsequent treatments if the disease comes back were the main things that influenced this result.